On the whole, this study not only highlights the potential value of S100A9 in predicting prognosis and immunotherapeutic response in GBM patients but also clarifies that S100A9 can promote the malignant progression of GBM and enhance the migration of M2 macrophages. Here, S100A9 is linked to glioblastoma.